Serum peptide profiling: identifying novel cancer biomarkers for early disease detection.
暂无分享,去创建一个
[1] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[2] L. Hann,et al. Advances in the detection of residual thyroid carcinoma. , 2001, Advances in internal medicine.
[3] T. Veenstra,et al. Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.
[4] S. Larson,et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[5] E. Petricoin,et al. Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.
[6] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[7] Emanuel F Petricoin,et al. Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. , 2003, Clinical chemistry.
[8] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[9] Richard J. Simpson,et al. Proteins and proteomics : a laboratory manual , 2003 .
[10] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[11] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[12] R. Aebersold,et al. Mass spectrometry-based proteomics , 2003, Nature.
[13] S. Larson,et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.
[14] Stephanie L. Lee,et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[15] P. Tempst,et al. Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.
[16] E. Holland,et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.